^
Association details:
| Biomarker: | PDGFRA rearrangement |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Imatinib Koanaa is indicated for the treatment of...adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
